A six-year patent war between Edwards Lifesciences (Irvine, California) and Medtronic (Minneapolis) has ended in a settlement that will require Medtronic to pay Edwards $750 million plus quarterly license royalty payments through April 2022. The agreement, reported Tuesday morning, was reached about a month after a Federal District Court ordered a preliminary injunction on U.S. sales of Medtronic's CoreValve transcatheter aortic valve replacement (TAVR/TAVI) system.